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The aim of present study was to describe the frequency of lipodystrophy syndrome asso-
ciated with HIV (LSHIV) and factors associated with dyslipidemia in Brazilian HIV infected
children.
HIV  infected children on antiretroviral treatment were evaluated (nutritional assessment,
physical examination, and laboratory tests) in this cross-sectional study. Univariate anal-
ysis  was performed using Mann–Whitney test or Fisher’s exact test followed by logistic
regression analysis. Presence of dyslipidemia (fasting cholesterol >200 mg/dl or triglycerides
>130 mg/dl) was the dependent variable.
90  children were enrolled. The mean age was 10.6 years (3–16 years), and 52 (58%)
were female. LSHIV was detected in 46 children (51%). Factors independently associ-
ated with dyslipidemia were: low intake of vegetables/fruits (OR = 3.47, 95%CI = 1.04–11.55),
current use of lopinavir/ritonavir (OR = 2.91, 95%CI = 1.11–7.67). In conclusion, LSHIV wasfrequently observed; inadequate dietary intake of sugars and fats, as well as current use of
lopinavir/ritonavir was associated with dyslipidemia.
© 2014 Elsevier Editora Ltda. All rights reserved.Introduction
Antiretroviral therapy (ARV) has changed human immuno-
deﬁciency virus (HIV) infection from a near-uniformly fatal
disease into a chronic, manageable illness. Before the avail-
ability of highly active antiretroviral therapy (HAART), 5–10%
∗ Corresponding author at: Rua Bruno Lobo, 50 – Ilha do Fundão, 21941-
E-mail address: cbhofer@hucff.ufrj.br (C.B. Hofer).
http://dx.doi.org/10.1016/j.bjid.2013.12.007
1413-8670/© 2014 Elsevier Editora Ltda. All rights reserved.of infected children survived for more  than three years after
their serologic diagnosis. Presently, the mortality rate has
decreased 70%.1 Children who survived HIV disease and AIDS
are a new challenge to HIV/AIDS care standards, since this612, Rio de Janeiro, Brazil.
is the ﬁrst generation of children who had the chance to
use HAART.2 One important challenge are the adverse events
associated with HAART, as they are described in adults as
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ell as in children. The lipodystrophy syndrome (LSHIV), the
edistribution of body fat (increased of centripetal fat – lipo-
ypertrophy and/or reduction of peripheral fat – lipoatrophy)
nd/or metabolic changes related to lipids proﬁle (dyslipide-
ia), and glucose intolerance, is one example of these adverse
vents.3–5 Another important issue is that HIV infected chil-
ren and their caregivers must also deal with other challenges,
elated to the prevailing socioeconomic conditions in develop-
ng countries, such as nutrition deprivation, poor nutritional
uality, or lack of regular physical activities.6
The aim of this study was to describe the prevalence of
SHIV and assess factors associated with dyslipidemia in HIV
nfected children treated with ARV, in a developing country
etting, considering their nutrition routine.
aterials  and  methods
his is a cross-sectional study conducted at the HIV clinic
f Instituto de Puericultura e Pediatria Martagão Gesteira, a
ertiary university pediatric hospital afﬁliated to the Univer-
idade Federal do Rio de Janeiro (IPPMG–UFRJ), from October
007 to January 2009. Children were included if they were two
r more  years old, HIV infected (conﬁrmed by two different
erological tests after 18 months of age), and on continuous
RV for at least the last three months prior to the interview.
Children were excluded if they had at the time of assess-
ent any of the following: severe infection, opportunistic
r bacterial infections, neoplastic disease, severe encephalo-
athy, wasting syndrome, or other metabolic disorders (such
s diabetes and inborn errors of metabolism).
The LSHIV was deﬁned as redistribution of body fat through
eripheral lipoatrophy, centripetal lipohypertrophy or mixed
orm – presence of the two types of redistribution, and/or
lso the presence of laboratory abnormalities (dyslipidemia),
ased on the criteria deﬁned by the European Pediatric Group
ipodystrophy.4 Dyslipidemia was deﬁned as serum choles-
erol ≥200 mg/dl and serum triglyceride ≥130 mg/dl, after 12 h
asting. Data were collected during the interview and same
ediatrician (LP) did all physical examinations. Height, weight,
riceps, subscapular, and brachial skin folds, as well as waist
ircumference were measured. Waist and arm circumference
ere measured with ordinary tape measure. Sub-scapular
nd arm skin folds were measured with Langer adipome-
er, properly calibrated. All measures were taken three times,
nd a mean of them was used. Collected data were com-
ared with the National Center for Health Statistics standard
rowth curve7 and transformed into z-scores using the for-
ula: z-score = (observed value − mean)/standard deviation.
nthropometric data were compared with the tables suitable
or age.8 Based on this anthropometric data, patients were
lassiﬁed as presenting peripheral lipoatrophy, centripetal
ipohypertrophy or mixed form of LSHIV. Patients were classi-
ed according to Tanner curve, by the pediatrician (LP).
Laboratory data on fasting cholesterol, triglycerides, glu-
ose, CD4+ T lymphocytes and viral load were also collected.
 food assessment survey was conducted assessing the 48-
 food recall. Results were analyzed according to quality and
uantity of each food group. It was considered inadequate if4;1 8(4):394–399 395
food intake was excessive and of poor quality and/or when it
was below the recommended for each particular food group.9
Antiretroviral therapy (ARV), but the zidovudine syrup used
for HIV vertical transmission prevention, was deﬁned as the
continuous use of any antiretroviral medication.
Food deprivation was considered when the patient was
starving and did not have food access enough his/her for well-
being for a week or more  during their lives (excluding dietary
recommendations).
The dependent variable was deﬁned as the presence or
absence of dyslipidemia in children. Independent variables
were gender, age, age at HIV diagnosis, length of HAART use,
CD4+ T lymphocytes percent cells, and viral load at the time of
the interview. Socioeconomic status and nutritional variables
were also evaluated: number of minimum Brazilian wages
per capita, history of food deprivation (when the child had
no food shortages due to poverty), inadequate intake (over or
lack thereof) of food groups, treatment compliance (deﬁned
as self-report adherence to at least 95% of prescribed doses of
ARV, three days prior the interview), physical activity (at least
30 min  per day, at least three times a week of any physical
activity).
Statistical analysis: the information obtained in the ques-
tionnaires were stored in a database using Access 2007®
software. Subsequently, the distribution of all continuous
variables was studied. The frequency of all the categorical
variables was described and univariate analysis of con-
tinuous variables was performed using Student’s t-test or
Mann–Whitney test if the variable did not have normal dis-
tribution. Univariate analysis of categorical variables was
performed using the Fisher exact test followed by multivari-
ate logistic regression analysis. The independent variables
selected to be included in the ﬁnal model were those that in
univariate analysis presented with p-value <0.15. Statistical
analysis was performed using the statistical package STATA
version 9.0, Texas, USA.
Ethical considerations:  this study was approved by IPPMG –
Ethical Committee.
Results
Ninety patients were enrolled. The mean age was 127.3
months, and 52 children were female. Among the female
group, 16 had history of menarche. The mean age of chil-
dren when they were ﬁrst diagnosed as HIV infected were 37
months.
Among the legal guardians of those children, 58 (64.4%)
were illiterate or had less than eight years of education.
All children were using ARV for at least three months, 32
were in their ﬁrst ARV regimen, 27 were in second ARV reg-
imen, and 31 had experienced three or more  ARV regimens.
Protease inhibitor (PI) based regimen was the current ARV regi-
men of 47 children (43 on lopinavir/ritonavir), whereas 33 were
on non-nucleoside reverse transcriptase inhibitors (NNRTI)
based regimens, and 10 patients were currently using nucleo-
side reverse transcriptase inhibitors (NRTI) based regimens.
According to the European Pediatric Group lipodystrophy
(4), 46 children presented lypodistrophy, as illustrated in Fig. 1.
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16 with clinical changes only
33 with laboratorial changes
(15 with only laboratorial changes and
15 with laboratorial and clinical changes)
44 without SLHIV
Clinical characteristics
10 with fat loss in the face
7 with zygomatic prominence
16 with fat loss in the limbs
7 with prominence of veins
2 with fat loss in the buttocks
1 with looseness in the buttocks
20 lipoatrophy
(2 only lipoatrophy)
29 lipohipertrophy
(11 only lipohipertrophy)
18 with both clinical
manifestation
29 with fat accumulation in
abdomen
6 with breast enlargement
15 with only
laboratorial
changes
90 children 46 with SLHIV
10 with high cholesterol
5 with clinical changes
20 with high triglycerides
7 with high cholesterol
3 with changes of cholesterol and triglycerides
2 with clinical changes
Laboratorial characteristics
 clinFig. 1 – Distribution of children according to
No children presented hyperglycemia. The mean cholesterol
was 153.2 mg/dl and the mean triglyceride was 111.4 mg/dl.
Overall mean body mass index (BMI) was 16.6 (z-score
−0.34), 17.1 for the group without LSHIV and 15.4 for the group
with LSHIV (p = 0.01).
In Table 1 shows demographic, clinical, and laboratory
characteristics according to the presence or absence of LSHIV
Demographic characteristics (income), clinical presentation
(category C event), laboratory data (nadir CD4+ lymphocytes),
use of ARV (lopinavir/ritonavir), and nutritional history were
associated with LSHIV.
CD4+ T lymphocytes varied from 45 to 2300 cells/mm3
(3–50%), and viral load at the moment of the interview varied
from undetectable to 80,4000 copies/mL. All variables with p-
value <0.15 were included in the multivariate analysis, except
BMI. Table 2 shows the result of the multivariate analysis.
Discussion
Among 90 children on ARV, 51% (46) were classiﬁed as having
LSHIV; 22% presented lipoatrophy and 32% lipohypertrophy.
The proportion of children affected by this syndrome ranged
from 20 to 50%, according to studies that evaluated different
10–14populations. In studies of adult groups, the prevalence
of LSHIV varied from 15 to 50%.15 An European study of 426
children found a 42% prevalence of clinical manifestations
of LSHIV.14 In a study involving 364 Ugandan children, theical and laboratory characteristics of SLHIV.
prevalence was lower: 27% presented clinical manifestations
and 34% laboratory abnormalities. Glucose metabolism abnor-
malities were not observed.16 Werner et al. in a study of 30
Brazilian children on ARV, found 88.3% with dyslipidemia (lab-
oratory abnormality) and only 13.9% with abnormal body fat
distribution.17
Since all clinical diagnoses were prone to observer bias, i.e.
even measuring circumferences and skin folds, the diagnosis
of LSHIV is ultimately based on investigator impression, and
hence we  studied risk factors associated with dyslipidemia,
considering nutritional history in our population.
Among the risk factors described in the literature, dysli-
pidemia was associated with older age, higher Tanner scores,
and use of ARV (such as stavudine, lopinavir/ritonavir, and
NNRTIs), white ethnicity, or higher viral load.11,14,16,18–20 In our
study, the risk factors independently associated with dyslipid-
emia were low intake of vegetables/fruits and current use of
lopinavir/ritonavir.
Arpadi et al. observed signiﬁcant associations between
worse virological and immunological status at the baseline
visit and the presence of changes consistent with LSHIV
in a group of children.18 A study of the European Pediatric
Group of Lipodystrophy demonstrated a signiﬁcant relation-
ship between children diagnosed as clinical category C (CDC)
with lower CD4+ T lymphocytes and onset of changes con-
sistent with LSHIV.4 A Thai pediatric study also described
an association between the baseline C clinical category
and LSHIV, but had not encountered any association with
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Table 1 – Demographic, clinical, and laboratory characteristics of the patients.
Patients with LSHIVb
(n = 46–51%)
Patients without
LSHIV (n = 44–49%)
ORd p-Value
Gender – female 27/46 (59%) 25/44 (57%) 1.08 0.86
HIV-vertically infected 44/46 (96%) 40/44 (91%) 0.16 0.51
Race – Caucasian 16/46 (35%) 11/44 (25%) 0.62 0.31
Admitted to the hospital in the last year 10/46 (22%) 4/44 (9%) 2.77 0.10a
Regular physical activity 11/46 (24%) 10/44 (23%) 1.06 0.89
History of food deprivation 13/46 (28%) 9/44 (20%) 1.53 0.39
Income – per person (minimum Brazilian salary wages (mean) 0.56 0.83 0.04a
Birth weight (mean – g) 2586 2329 0.42
Age (at the interview), months (mean – months) 121.8 133.1 0.19
Clinical classiﬁcation C (CDC) 23/46 (50%) 15/44 (34%) 1.93 0.07
On any protease inhibitor 27/46 (59%) 20/44 (45%) 1.71 0.21
On LPV/rc 27/46 (59%) 16/44 (36%) 2.49 0.03a
Time on the current ARV regimen (mean – months) 25.5 28.7 0.53
100% adherence, 3 days prior to the interview 17/46 (37%) 11/44 (25%) 1.76 0.22
Inadequate intake of sugars and fat 23/46 (50%) 10/44 (23%) 3.40 <0.01a
Inadequate intake of milk and dairy products 16/46 (35%) 10/44 (23%) 1.81 0.21
Inadequate intake of protein 12/46 (26%) 8/44 (18%) 1.59 0.37
Inadequate intake of vegetables/fruits 40/46 (87%) 29/44 (67%) 3.40 0.02a
Inadequate intake of cereals 9/46 (20%) 4/44 (9%) 2.43 0.18
Nadir % CD4+ T cells (mean) 15.17 19.70 0.06a
Actual % CD4+ T cells (mean) 25.67 25.93 0.81
Baseline viral load – log (mean) 5.84 5.79 0.80
Current viral load – log (mean) 4.47 3.74 0.19
Current ASTe – units/mL (mean) 33 28 0.07a
Current ALTf – units/mL (mean) 20 18 0.54
a Variables included in multivariate analysis.
b LSHIV: lipodystrophy syndrome associated with HIV.
c Lopinavir/ritonavir.
d Odds ratio.
C
r
p
i
F
d
u
l
p
pe Aspartate aminotransferase.
f Alanine aminotransferase.
D4+ T lymphocytes.21 In our study, we  did not observe a
elationship between dyslipidemia and immunosuppression,
robably because this association is related with clinical man-
festations of the LSHIV more  than laboratory abnormalities.
lint et al. suggested that both treatment with antiretroviral
rugs and some chronic inﬂammatory response to HIV stim-
lated the homeostatic response to stress at the cellular level,
eading to adverse effects on the adipocytes metabolism. This
rocess leads to a cycle of pathological lipotoxicity, lipoatro-
hy and, consequently, the phenotype of fat distribution with
Table 2 – Multivariate analysis – factors associated with LSHIV.a
Income – per person (minimum Brazilian wage) salary wages (mean) 
Nadir % CD4+ per cell 
Inadequate intake of vegetables/fruits 
Inadequate intake of sugars and fat 
On LPV/rb
Admitted to the hospital in the last year 
Current ASTe – per Unit/mL 
a LSHIV: lipodystrophy syndrome associated with HIV.
b Lopinavir/ritonavir.
c Odds ratio.
d 95% conﬁdence interval.
e Aspartate aminotransferase.high waist–hip ratio, and of course the more  severe HIV disease
the child had, the worse the homeostatic response to stress
at the cellular level they would present.22 Another important
issue possibly associated with the inﬂammatory response was
the positive association between aspartate aminotransferase
(AST) and the presence of LSHIV. AST is a component of the
AST platelet ratio index (APRI). This index (AST/platelets) is
associated with liver ﬁbrosis among HIV infected patients with
and without other viral hepatitis23 patients, and a possible eti-
ology for this ﬁbrosis is the inﬂammatory disorder associated
ORc 95%CId p-Value
0.96 0.77–1.21 0.74
0.96 0.92–1.00 0.08
1.81 0.56–5.84 0.32
3.05 1.10–8.46 0.03
2.51 0.94–6.75 0.06
1.87 0.45–7.74 0.39
1.05 1.00–1.11 0.05
i s . 2 0
r
1
1
1
1
1
1
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with HIV. The increased AST observed in the univariate analy-
sis would also be a surrogate marker of fatty hepatic steatosis,
more frequently described in obese children. However, if this
was the case, the alanine aminotransferase should have also
been elevated, which was not the case.24 Another hypothe-
sis for this ﬁnding is that AST is increased due to the use of
ARV; Ottop et al. studied 230 HIV infected adults in Cameroon,
and patients who were on ARV had higher AST levels when
compared with those without ARV.25
Although interventions to avoid and improve dyslipidemia
were frequently based on improving the quality of diet,26 few
studies evaluated the diet among LSHIV patients, and none in
children, including children from developing countries.
The analysis of dietary survey was carried out accord-
ing to speciﬁc food groups and was considered inadequate
when above or below the recommended daily amount for the
age-speciﬁc children. Individually, we observed that lower veg-
etables and sugar intake were signiﬁcantly associated with
LSHIV. These data support the hypothesis that, despite the
absence of food deprivation, the quality of nutrition was far
below the recommended levels. Such children with poor nutri-
tion have greater chance of developing dyslipidemia. A review
by Almeida et al., of 20 dietary intervention studies in adults,
concluded that changes in lifestyle, diet and physical activ-
ity were always recommended as the ﬁrst approach in the
treatment of dyslipidemia, related or not to HIV, and our
results corroborate this ﬁndings.27 In conclusion, any inter-
vention to tackle dyslipidemia in children must aim at not only
improving nutrition quality of the children, but also, whenever
possible avoiding the use of ARV that would raise cholesterol
or triglyceride levels, such as lopinavir/ritonavir.28
The design of this study was cross-sectional and aimed
only to describe the presence of LSHIV and factors associated
with dyslipidemia among children followed at the IPPMG’s
outpatient clinic. Some of the variables, such as the use of
stavudine and lack of physical activity, although biologically
plausible were not associated with dyslipidemia in our study,
possibly due to the small sample size available.
We  believe that longitudinal studies to investigate the role
of diet on LSHIV prevention in this population must be pur-
sued.
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